Terms: = Breast cancer AND SLC34A2, ENSG00000157765, O95436, NPTIIb, NAPI-IIb, NAPI-3B, FLJ90534, 10568 AND Treatment
5 results:
1. Distinct molecular subtypes of papillary thyroid carcinoma and gene signature with diagnostic capability.
Hong S; Xie Y; Cheng Z; Li J; He W; Guo Z; Zhang Q; Peng S; He M; Yu S; Xu L; Liu R; Xu T; Zhang Y; Li Y; Wang J; Lv W; Yu J; Xiao H
Oncogene; 2022 Nov; 41(47):5121-5132. PubMed ID: 36253446
[TBL] [Abstract] [Full Text] [Related]
2. MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung cancers Driven by
Sato H; Schoenfeld AJ; Siau E; Lu YC; Tai H; Suzawa K; Kubota D; Lui AJW; Qeriqi B; Mattar M; Offin M; Sakaguchi M; Toyooka S; Drilon A; Rosen NX; Kris MG; Solit D; De Stanchina E; Davare MA; Riely GJ; Ladanyi M; Somwar R
Clin Cancer Res; 2020 Jun; 26(12):2932-2945. PubMed ID: 32122926
[TBL] [Abstract] [Full Text] [Related]
3. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
[TBL] [Abstract] [Full Text] [Related]
4. Solute carrier family 34 member 2 overexpression contributes to tumor growth and poor patient survival in colorectal cancer.
Liu L; Yang Y; Zhou X; Yan X; Wu Z
Biomed Pharmacother; 2018 Mar; 99():645-654. PubMed ID: 29653487
[TBL] [Abstract] [Full Text] [Related]
5. Enhanced slc34a2 in breast cancer stem cell-like cells induces chemotherapeutic resistance to doxorubicin via slc34a2-Bmi1-ABCC5 signaling.
Ge G; Zhou C; Ren Y; Tang X; Wang K; Zhang W; Niu L; Zhou Y; Yan Y; He J
Tumour Biol; 2016 Apr; 37(4):5049-62. PubMed ID: 26546432
[TBL] [Abstract] [Full Text] [Related]